We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADVM
126
DELISTED
Adverum Biotechnologies
ADVM
$1.86M 0.1%
19,513
-37,913
-66% -$3.33M
ACUR
127
DELISTED
Acura Pharmaceuticals
ACUR
$1.84M 0.1%
727,865
-15,738
-2% -$38.3K
RGLS
128
DELISTED
Regulus Therapeutics
RGLS
$1.83M 0.1%
1,750
-1,221
-41% -$1.22M
GALT icon
129
Galectin Therapeutics
GALT
$223M
$1.78M 0.1%
+1,086,615
New +$2.49M
RIBT
130
DELISTED
RiceBran Technologies
RIBT
$1.77M 0.1%
93,344
+3,147
+3% +$64.7K
LJPC
131
DELISTED
La Jolla Pharmaceutical Company
LJPC
$1.76M 0.1%
65,158
-19,853
-23% -$541K
ZLTQ
132
CALL
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$1.74M 0.1%
610
-390
-39% -$12.3K
BCRX icon
133
BioCryst Pharmaceuticals
BCRX
$2.48B
$1.71M 0.09%
165,529
+79,134
+92% +$787K
LUMO
134
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.7M 0.09%
52
+4
+8% +$1.3K
DBVT
135
DBV Technologies
DBVT
$799M
$1.69M 0.09%
4,659
+2,805
+151% +$980K
MNOV icon
136
MediciNova
MNOV
$65.5M
$1.69M 0.09%
474,803
-25,197
-5% -$80K
FOLD
137
CALL
DELISTED
Amicus Therapeutics
FOLD
$1.69M 0.09%
1,737
+1,007
+138% +$9.07K
XTLB
138
XTL Biopharmaceuticals
XTLB
$7.27M
$1.67M 0.09%
55,598
-1,896
-3% -$63.7K
SGYPW
139
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$1.65M 0.09%
291,306
+100
+0% +$198
AMRN
140
CALL
Amarin Corp
AMRN
$293M
$1.64M 0.09%
434
+25
+6% +$982
QRHC icon
141
Quest Resource Holding
QRHC
$28.3M
$1.63M 0.09%
304,380
-89,170
-23% -$529K
INSM icon
142
PUT
Insmed
INSM
$22.6B
$1.58M 0.09%
870
+106
+14% +$1.87K
SGYPW
143
CALL
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$1.58M 0.09%
2,785
– –
IMUC
144
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$1.58M 0.09%
111,098
+6,867
+7% +$113K
QURE icon
145
CALL
uniQure
QURE
$2.52B
$1.57M 0.09%
950
+106
+13% +$1.96K
WINT
146
DELISTED
Windtree Therapeutics Inc
WINT
$1.57M 0.09%
524,253
+188,285
+56% +$772K
INFI
147
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.55M 0.09%
1,971
– –
HALO icon
148
PUT
Halozyme
HALO
$9.9B
$1.46M 0.08%
840
– –
ADYX
149
DELISTED
Adynxx Inc
ADYX
$1.42M 0.08%
11,080
+5,578
+101% +$953K
TROVW
150
CALL
DELISTED
TrovaGene, Inc. Warrant
TROVW
$1.4M 0.08%
2,600
– –
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.